Genetic Mutation Tied to Rare Adolescent Liver Cancer

2014 Cancer Discovery  
Précis: Ceritinib, a next-generation ALK inhibitor, has potent activity in preclinical models of crizotinib-naïve and crizotinibresistant ALK-rearranged non-small cell lung cancer.
doi:10.1158/2159-8290.cd-nb2014-048 fatcat:uf4k6b6xvvggbcfrw7eoyxx3tu